Promoting cost effective prescribingBMJ 1995; 311 doi: https://doi.org/10.1136/bmj.311.6997.126b (Published 08 July 1995) Cite this as: BMJ 1995;311:126
- Adrian Towse,
- Nicholas Wells
- Director Office of Health Economics, London SW1A 2DY
- Head of Health Economics Glaxo Pharmaceuticals UK, Uxbridge, Middlesex UB11 1BT
Cost effectiveness studies may not be cost effective
EDITOR,--Nick Freemantle and colleagues criticise the NHS for lagging behind Australia and Canada in promoting cost effective prescribing.1 As members of the working group that agreed the British guidance on conducting economic evaluations2 we take issue with their claim that these countries have a preferable approach.
There is no evidence that Australia and Canada have more cost effective prescribing than the United Kingdom. They have centralised reimbursement lists (federal and provincial, respectively), requiring the …